UNASSIGNED: The woman who was 52 years old at diagnosis of adenocarcinoma of the right colon (T3/N0/M1) with metastases to the lung, liver, ovary, and other soft tissues received first-line fluoropyrimidine-based chemotherapy (FOLFOX/FOLFIRI plus bevacizumab) intermittently for approximately 8.5 years with generally stable disease, and second-line FOLFIRI plus radiotherapy. After progression on second-line therapy, the patient initiated treatment with FTD/TPI 35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. She received a total of 38 cycles of FTD/TPI over a period of 34 months achieving a partial response, maintained performance status, and improved quality of life. Neutropenia was successfully managed with FTD/TPI dose delays or reductions.
UNASSIGNED: This heavily pre-treated patient with mCRC demonstrated impressive long-term survival and maintenance of good quality of life with FTD/TPI treatment.
■诊断为右结肠腺癌(T3/N0/M1)并向肺转移的52岁女性,肝脏,子房,和其他软组织接受以氟嘧啶为基础的一线化疗(FOLFOX/FOLFIRI加贝伐单抗)间歇性约8.5年,疾病总体稳定,和二线FOLFIRI加放疗。在二线治疗进展后,患者在每个28天周期的第1-5天和第8-12天开始使用FTD/TPI35mg/m2每日2次治疗.在34个月的时间里,她总共收到了38个周期的FTD/TPI,实现了部分响应,保持的性能状态,提高了生活质量。中性粒细胞减少症通过FTD/TPI剂量延迟或减少成功治疗。
■这位经过大量预处理的mCRC患者在FTD/TPI治疗下表现出令人印象深刻的长期生存率和良好的生活质量。